These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1320 related items for PubMed ID: 33020239

  • 21. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
    Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, Morris DG, Heng DYC, Pabani A, Dean M, Navani V.
    JAMA Netw Open; 2024 Jan 02; 7(1):e2352302. PubMed ID: 38236598
    [Abstract] [Full Text] [Related]

  • 22. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
    Enright TL, Witt JS, Burr AR, Yadav P, Leal T, Baschnagel AM.
    Clin Lung Cancer; 2021 Mar 02; 22(2):110-119. PubMed ID: 33281062
    [Abstract] [Full Text] [Related]

  • 23. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, Fernandes R.
    Cancer Treat Rev; 2021 Jan 02; 92():102134. PubMed ID: 33302134
    [Abstract] [Full Text] [Related]

  • 24. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
    Zheng L, Xiong A, Wang S, Xu J, Shen Y, Zhong R, Lu J, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X.
    Front Immunol; 2023 Jan 02; 14():1094378. PubMed ID: 36776882
    [Abstract] [Full Text] [Related]

  • 25. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF, Feng JK, Xiang YJ, Wang K, Zhou LP, Liu ZH, Cheng YQ, Shi J, Guo WX, Cheng SQ.
    BMC Cancer; 2023 Jun 15; 23(1):547. PubMed ID: 37322411
    [Abstract] [Full Text] [Related]

  • 26. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
    Kowalski ES, Remick JS, Sun K, Alexander GS, Khairnar R, Morse E, Cherng HR, Berg LJ, Poirier Y, Lamichhane N, Becker S, Chen S, Molitoris JK, Kwok Y, Regine WF, Mishra MV.
    Radiat Oncol; 2020 Oct 27; 15(1):245. PubMed ID: 33109224
    [Abstract] [Full Text] [Related]

  • 27. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X, Wang Y, Li X, Feng G, Hu S, Bai Y.
    Front Immunol; 2021 Oct 27; 12():638763. PubMed ID: 34305884
    [Abstract] [Full Text] [Related]

  • 28. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T, Yu M, Yu Y, Wang K, Tian P, Luo Z, Ding Z, Wang Y, Gong Y, Zhu J, Zou B, Sio TT, Alves A, Liu Y, Huang M, Lu Y.
    Transl Lung Cancer Res; 2022 Jun 27; 11(6):1027-1037. PubMed ID: 35832458
    [Abstract] [Full Text] [Related]

  • 29. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
    Lu PH, Tsai TC, Chang JW, Deng ST, Cheng CY.
    J Clin Pharm Ther; 2021 Apr 27; 46(2):408-414. PubMed ID: 33332621
    [Abstract] [Full Text] [Related]

  • 30. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.
    Nakahama K, Izumi M, Yoshimoto N, Fukui M, Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T.
    Anticancer Res; 2023 May 27; 43(5):2185-2197. PubMed ID: 37097681
    [Abstract] [Full Text] [Related]

  • 31. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
    Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, Ingle M, Brown A, Gujral D, Partridge S, Sarwar N, Gonzalez M, Bendle M, Lewanski C, Newsom-Davis T, Allara E, Bower M.
    JAMA Oncol; 2019 Dec 01; 5(12):1774-1778. PubMed ID: 31513236
    [Abstract] [Full Text] [Related]

  • 32. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, Xin Y, Wang Y, Yang C, Cheng Y.
    J Clin Lab Anal; 2019 Oct 01; 33(8):e22964. PubMed ID: 31282096
    [Abstract] [Full Text] [Related]

  • 33. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A.
    Eur J Cancer; 2021 Jan 01; 142():18-28. PubMed ID: 33212418
    [Abstract] [Full Text] [Related]

  • 34. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
    Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S, Villeminey CV, Piketty AC, Rassy N, Ulmann G, Damotte D, Mansuet-Lupo A, Giraud F, Alifano M, Wislez M, Alexandre J, Jouinot A, Goldwasser F.
    EBioMedicine; 2021 Nov 01; 73():103630. PubMed ID: 34688030
    [Abstract] [Full Text] [Related]

  • 35. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT, Su CT, Hu M, Taylor JMG, Daignault-Newton S, Kellezi O, Dahl MN, Shah MA, Erickson S, Lora J, Hamasha R, Ali A, Yancey S, Kiros L, Balicki HM, Winfield DC, Green MD, Alva AS.
    Urol Oncol; 2021 Jul 01; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [Abstract] [Full Text] [Related]

  • 36. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
    Lefebvre C, Martin E, Hendriks LEL, Veillon R, Puisset F, Mezquita L, Ferrara R, Sabatier M, Filleron T, Dingemans AC, Besse B, Raherisson C, Mazières J.
    Respir Med Res; 2020 Nov 01; 78():100788. PubMed ID: 32980653
    [Abstract] [Full Text] [Related]

  • 37. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Young M, Tapia JC, Szabados B, Jovaisaite A, Jackson-Spence F, Nally E, Powles T.
    Clin Genitourin Cancer; 2024 Jun 01; 22(3):102072. PubMed ID: 38615487
    [Abstract] [Full Text] [Related]

  • 38. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N, Jiang J, Tang S, Sun G.
    Int Immunopharmacol; 2020 Aug 01; 85():106677. PubMed ID: 32531712
    [Abstract] [Full Text] [Related]

  • 39. Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.
    Öjlert ÅK, Nebdal D, Lund-Iversen M, Åstrøm Ellefsen R, Brustugun OT, Gran JM, Halvorsen AR, Helland Å.
    Acta Oncol; 2021 Feb 01; 60(2):149-156. PubMed ID: 33356733
    [Abstract] [Full Text] [Related]

  • 40. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I, Mezquita L, Rossoni C, Auclin E, Kossai M, Aboubakar F, Le Moulec S, Massé J, Masson M, Radosevic-Robin N, Alemany P, Rouanne M, Bluthgen V, Hendriks L, Caramella C, Gazzah A, Planchard D, Pignon JP, Besse B, Adam J.
    Eur J Cancer; 2021 Mar 01; 145():221-229. PubMed ID: 33516050
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 66.